What is the role of larotrectinib in the treatment of colon cancer?

Updated: Apr 15, 2020
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print

Larotrectinib is a highly selective inhibitor of tropomyosin receptor kinases A, B, and C (TRKA, TRKB, TRKC), which are encoded by NTRK genes. In November 2018, the FDA granted tissue-agnostic approval for larotrectinib for adult and pediatric patients who meet the following criteria [129] :

  • Have solid tumors that harbor an  NTRK gene fusion without a known acquired resistance mutation (note that  NTRK fusions can be hard to detect and are found in only about 1% of colorectal cancers)
  • Have metastatic disease or disease that has progressed after treatment
  • Are likely to experience severe morbidity as a result of surgery
  • Lack alternative satisfactory treatments

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!